+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Inflammation Drug"

From
From
From
From
From
Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2020 - Product Thumbnail Image

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 693 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Review, H2 2020 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 1191 Pages
  • Global
From
N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019 - Product Thumbnail Image

N-Formyl Peptide Receptor 2 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 32 Pages
  • Global
From
Endometriosis - Global Drug Forecast and Market Analysis to 2030 - Product Thumbnail Image

Endometriosis - Global Drug Forecast and Market Analysis to 2030

  • Report
  • December 2021
  • 124 Pages
  • Global
From
From
From
From
Loading Indicator

The Immune Disorders Drugs market is composed of drugs used to treat a variety of conditions related to the immune system. These drugs are used to treat autoimmune diseases, allergies, and other conditions that affect the body's ability to fight off infection. Inflammation drugs are a subset of these drugs, used to reduce inflammation and swelling caused by an immune response. These drugs can be used to treat a variety of conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease. They can also be used to reduce the risk of infection in patients with weakened immune systems. Inflammation drugs are typically administered orally or intravenously, and can be taken as a single dose or as part of a longer-term treatment plan. Common side effects of these drugs include nausea, vomiting, and diarrhea. Companies in the Immune Disorders Drugs market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more